Healthy VolunteersEPICAPTURENCT06934902
Attentional Capture by Real-life Episodic Information
A study testing Old vs new objects" encoding phase and fMRI and " incongruent vs. congruent contexts " encoding phase and fMRI in people with Healthy Volunteers and Attentional Capture, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
Attention facilitates the allocation of processing resources and the control of behavior among competing stimuli. Current research focuses primarily on attention control networks in the dorsal frontoparietal (DAN) and ventral (VAN) cortex. Read more about this study
- Who is it for?
- Ages 18 to 40 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteers, Attentional Capture
- What is being tested?
- Old vs new objects" encoding phase and fMRI and " incongruent vs. congruent contexts " encoding phase and fMRI
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 86 participants
- Where
- 1 siteFrance
- Study dates
- 21 Oct 2026to 21 Nov 2029
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 40 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Be 18 years old to 40 years old
- Be right-handed
- Do not wear glasses
- Have a mobile-phone compatible with the application, minimum 6rd generation Android operating system, with geo-localization activated and accepted by the user
- Undertake to comply with the instructions and recommendations for MRI examination
- Provide informed written consent to participate in the study
Who cannot join
- History of known neurological or psychiatric illness
- Cognitive problems limiting the understanding of instructions
- Recent taking psychotropic drugs (antidepressants, anxiolytics, antipsychotics). The main treatments not authorized during this research are the following: Psychotropic treatments (drugs that can induce changes in perception, sensation, mood, consciousness or behavior). Like what:
- Antipsychotics (valproic acid, amisulpride, aripiprazole, clozapine, cyamemazin, haloperidol, loxapine, olanzapine, risperidone).
- Antidepressants (Amitriptyline, Citalopram, Clomipramine, Duloxetine, Escitalopam, Fluoxetine, Mianserine, Mirtazapine, Nortriptyline, Paroxetine, Sertraline, Venlafaxine).
- Anxyolitics
Show all 20Show fewer
- Pregnant or breastfeeding women
- Persons deprived of their liberty by a judicial or administrative decision
- Persons admitted to a health or social institution for purposes other than research
- Adults subject to a legal protection measure (guardianship, curatorship)
- Persons not affiliated to a social security scheme or beneficiaries of a similar scheme
- Participation in another research study of the current study
- Contraindication for fMRI scanning
- Participant not agreeing to be informed in the event of the incidental discovery of an anomaly on MRI
- For visit number 2 :
- Alcohol consumption (> 3 drinks) in the 24h before the experiment
- Alcohol consumption the day of the experiment
- Cafeine consumption 1 hour or less before the experiment
- Drug consumption within the 24h preceding the experiment
- Antimalarial treatment within the 3 days preceding the experiment
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
UCBL1, CRNL Inserm U1028, CNRS UMR5292, équipe IMPACT
Bron, Rhone, 69500
Emiliano Macaluso, Pr, 04 72 91 34 07 ext. +33, emiliano.macaluso@univ-lyon1.fr
Samy adraim FOUDIL, 07 77 36 37 68 ext. +33, samy@samalgo.com
About this study
Attention facilitates the allocation of processing resources and the control of behavior among competing stimuli. Current research focuses primarily on attention control networks in the dorsal frontoparietal (DAN) and ventral (VAN) cortex. However, typical laboratory experiments emphasize task-specific processing, neglecting the possible role of memory. Although a few studies have examined the contribution of memory to attention control, they have generally used simple tasks in the laboratory. These tasks are unlikely to produce true traces of episodic memory, which are - by definition - characterized by complex contextual information (what, where, when) and personal relevance. This research will therefore use an innovative protocol based on mobile phone technology to generate episodes in the participants' real lives and then measure the impact of these past personal experiences on attention allocation (by assessing eye movements) and on the activity of the DAN/VAN system (using functional imaging).
The main hypothesis of the study is that knowledge acquired during everyday life contributes to the subsequent allocation of processing resources, via engagement of the DAN/VAN attention systems.
- Conditions
- Healthy Volunteers, Attentional Capture
- Being tested
- Old vs new objects" encoding phase and fMRI, " incongruent vs. congruent contexts " encoding phase and fMRI
- Keywords
- Healthy volunteers, Attentional capture, real-life episodic information
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Old vs new objects" encoding phase and fMRIBehavioural
During the encoding phase, a set of 60 objects will be presented to the participants in their everyday life. Pictures of objects sent to their app mobile phone over a period of 3 weeks.
The following week, participants will have an fMRI. During fMRI, participants will see objects already seen or not seen during the encoding phase.
" incongruent vs. congruent contexts " encoding phase and fMRIBehavioural
During the encoding phase, a set of 60 objects will be presented to the participants in their everyday life. Pictures of objects sent to their app mobile phone over a period of 3 weeks. This time, the objects will be chosen according to the participant's location.
The following week, participants will have an fMRI. During fMRI, participants will see objects encoding in congruent/incongruent contexts.
| Study group | Role | What they receive |
|---|---|---|
| Old vs new objects | Experimental | The following week after the "Old vs new objects" encoding phase of 3 weeks, participants will have an fMRI.
During fMRI, participants will see objects already seen or not seen during the encoding phase. Receives: Behavioral: Old vs new objects" encoding phase and fMRI |
| incongruent vs. congruent contexts | Experimental | The following week after the "incongruent vs. congruent contexts" encoding phase of 3 weeks, participants will have an fMRI.
During fMRI, participants will see objects encoding in congruent or incongruent contexts. Receives: Behavioral: " incongruent vs. congruent contexts " encoding phase and fMRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
activation pattern in fMRI: "old vs. new" objects (intervention 1)
activation pattern in DAN/VAN system in fMRI experiments for the comparison of trials with gaze directed towards "seen/old vs. unseen/new" objects.
Measured: One time during the week after the 3 weeks encoding phase
Secondary outcomes (2)
activation pattern in fMRI: "place" images in intervention 1
activation pattern in DAN/VAN system in fMRI experiments when participants direct gaze towards the image depicting the location where they were at the time they received an object during the encoding phase, compared with trials when gaze is directed towards the image of a place that was not visited during the encoding phase.
Measured: One time during the week after the 3 weeks encoding phase
activation pattern in fMRI: incongruent vs. congruent contexts (intervention 2)
activation pattern in DAN/VAN system in fMRI experiments for the comparison of trials with gaze directed towards old/seen objects encoded in incongruent vs congruent contexts.
Measured: One time during the week after the 3 weeks encoding phase
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2025
- Study start21 Oct 2026
- Primary completion21 Nov 2029 (estimated)
- Study completion21 Nov 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy VolunteersStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- Our main hypothesis concerning the role of personal past experiences in guiding spatial attention via the dorsal and ventral attention control system (DAN/VAN) will be tested in two fMRI studies in healthy participants. The use of mobile-mobile technology will allow us to control the formation of episodic memory traces in the real-world. In the testing phase, eye-tracking will permit us to assess the allocation of spatial attention, and fMRI will assess the activation of the attention systems as a function of condition (gaze/attention towards elements associated with previous personal experiences, i.e. pictures of old/seen objects or places, vs. pictures of new/unseen objects/places).
- Masking
- None (open label)
- Enrolment
- 86 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06934902
- Sponsor's protocol ID
- 69HCL25_0108
- Acronym
- EPICAPTURE
- Status last verified
- Oct 2026
- First submitted
- 11 Apr 2025
- Last updated
- 23 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No